Metraipolis › archive › dc_f2abf885c142
Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab — Europe PMC PMID:42036830
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42036830
- DOI
- 10.1002/acn3.70392
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T05:18:59.740Z
- SHA-256 of the archived text
5614ec9ad7232b8ad1355e8039fc5d3d67d50cdf4bbb63b6712cbc49c571dbc2- Stable URL of this page
https://metraipolis.com/documento/dc_f2abf885c142
How to cite
Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab — Europe PMC PMID:42036830 — Europe PMC (en), https://europepmc.org/article/MED/42036830 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f2abf885c142 (Metraipolis archive dc_f2abf885c142, sha256 5614ec9ad7232b8ad1355e8039fc5d3d67d50cdf4bbb63b6712cbc49c571dbc2)
BibTeX
@misc{dcf2abf885c142,
title = {Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparison With Rituximab — Europe PMC PMID:42036830},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42036830},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f2abf885c142; sha256 5614ec9ad7232b8ad1355e8039fc5d3d67d50cdf4bbb63b6712cbc49c571dbc2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42036830. Agents can read the archived copy with the MCP tool read_document.